Yasuhiro Fujiwara

List of Publications by Year
in descending order

211 papers	8,280 citations	65103 42 h-index	59438 82 g-index
229 all docs	229 docs citations	229 times ranked	12864 citing authors

#	Article	IF	Citations
1	Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. Journal of Clinical Oncology, 2010, 28, 5132-5139.	15.4	1,414
2	Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibodyâ€“drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncology, The, 2017, 18, 1512-1522.	10.8	355
3	Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Science, 2016, 107, 326-334.	4.0	289
4	Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Research and Treatment, 2012, 132, 793-805.	2.5	277
5	Feasibility and utility of a panel testing for 114 cancerâ€associated genes in a clinical setting: A hospitalâ€based study. Cancer Science, 2019, 110, 1480-1490.	4.0	261
6	⁶⁴Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer. Journal of Nuclear Medicine, 2013, 54, 1869-1875.	6.1	243
7	Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Supportive Care in Cancer, 2016, 24, 447-455.	2.3	152
8	Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Research and Treatment, 2006, 99, 9-17.	2.5	136
9	Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. Journal of Neuro-Oncology, 2009, 93, 205-212.	3.0	127
10	Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid. Clinical Cancer Research, 2012, 18, 4841-4849.	7.2	126
11	Disruption of the blood brain barrier by brain metastases of tripleâ€negative and basalâ€type breast cancer but not HER2/neuâ€positive breast cancer. Cancer, 2010, 116, 302-308.	4.1	118
12	Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. ESMO Open, 2017, 2, e000150.	4.4	108
13	Expression of insulin-like growth factor 1 receptor in primary breast cancer: Immunohistochemical analysis. Human Pathology, 2004, 35, 1537-1542.	2.3	105
14	Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. International Journal of Clinical Oncology, 2013, 18, 132-138.	2.3	104
15	The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: The relationship between the outcome and the clinicopathological characteristics. Breast, 2012, 21, 289-295.	2.3	99
16	A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. British Journal of Cancer, 2019, 120, 475-480.	6.6	99
17	Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochemical and Biophysical Research Communications, 1992, 188, 571-577.	2.2	97
18	Efficacy of everolimus, a novel m<scp>TOR</scp> inhibitor, against basalâ€like tripleâ€negative breast cancer cells. Cancer Science, 2012, 103, 1665-1671.	4.0	90

#	Article	IF	Citations
19	Pharmacokinetics of (glycolato-0,0?)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemotherapy and Pharmacology, 1989, 23, 243-246.	2.4	88
20	Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Research and Treatment, 2010, 119, 127-136.	2.5	85
21	64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Research, 2015, 5, 8.	2.6	85
22	LEVELS OF GLUTATHIONES TRANSFERASE Ï€ mRNA IN HUMAN LUNG CANCER CELL LINES CORRELATE WITH THE RESISTANCE TO CISPLATIN AND CARBOPLATIN. Japanese Journal of Cancer Research, 1988, 79, 301-304.	1.6	79
23	Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancerâ€“related bone metastases. Cancer Science, 2008, 99, 1237-1242.	4.0	78
24	Nâ€Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Science, 2008, 99, 1611-1617.	4.0	76
25	Determinants of Drug Response in a Cisplatin-resistant Human Lung Cancer Cell Line. Japanese Journal of Cancer Research, 1990, 81, 527-535.	1.6	73
26	Enhancement of Tumor Radio-response by Irinotecan in Human Lung Tumor Xenografts. Japanese Journal of Cancer Research, 1997, 88, 218-223.	1.6	73
27	In vitro antitumor activity of mitomycin C derivative (RM-49) and new anticancer antibiotics (FK973) against lung cancer cell lines determined by tetrazolium dye (MTT) assay. Cancer Chemotherapy and Pharmacology, 1988, 22, 246-250.	2.4	70
28	Physiciansâ€™ knowledge, attitude, and behavior regarding fertility issues for young breast cancer patients: a national survey for breast care specialists. Breast Cancer, 2013, 20, 230-240.	3.0	70
29	Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemotherapy and Pharmacology, 1990, 26, 313-317.	2.4	64
30	Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Research and Treatment, 2014, 145, 401-409.	2.5	63
31	Feasibility and usefulness of the â€˜Distress Screening Program in Ambulatory Careâ€™ in clinical oncology practice. Psycho-Oncology, 2010, 19, 718-725.	2.5	59
32	Prognostic Significance of p53 andrasGene Abnormalities in Lung Adenocarcinoma Patients with Stage I Disease after Curative Resection. Japanese Journal of Cancer Research, 1994, 85, 1240-1246.	1.6	55
33	Quantitative assessment of appearance changes and related distress in cancer patients. Psycho-Oncology, 2013, 22, 2140-2147.	2.5	53
34	The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecologic Oncology, 2006, 100, 412-416.	1.4	50
35	Development and validation of diagnostic prediction model for solitary pulmonary nodules. Respirology, 2007, 12, 856-862.	2.9	50
36	High-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma. Biomedical Applications, 1995, 670, 309-316.	1.7	49

#	Article	IF	Citations
37	The Role of Glucuronidation in 7-Ethyl-10-hydroxycamptothecin Resistancein vitro. Japanese Journal of Cancer Research, 1997, 88, 1211-1217.	1.6	49
38	Applications of MALDI mass spectrometry imaging for pharmacokinetic studies during drug development. Drug Metabolism and Pharmacokinetics, 2019, 34, 209-216.	2.3	49
39	21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients. Breast, 2009, 18, 171-174.	2.3	48
40	Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials. Molecular Cancer, 2016, 15, 73.	20.2	48
41	The notorious â€œdrug lagâ€•for oncology drugs in Japan. Investigational New Drugs, 2011, 29, 706-712.	2.7	46
42	The Mechanism of the Difference in Cellular Uptake of Platinum Derivatives in Non-small Cell Lung Cancer Cell Line (PC-14) and Its Cisplatin-resistant Subline (PC-14/CDDP). Japanese Journal of Cancer Research, 1993, 84, 83-92.	1.6	45
43	Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. Pathology Research and Practice, 2006, 202, 705-712.	2.3	45
44	First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. Breast Cancer Research and Treatment, 2011, 129, 829-838.	2.5	43
45	Factors That Affect the Duration of the Interval Between the Completion of Palliative Chemotherapy and Death. Oncologist, 2009, 14, 752-759.	4.1	42
46	Weekly Paclitaxel and Carboplatin against Advanced Transitional Cell Cancer after Failure of a Platinum-Based Regimen. European Urology, 2007, 52, 1115-1122.	5.0	40
47	Increased expression of theMRP5 gene is associated with exposure to platinum drugs in lung cancer. International Journal of Cancer, 2000, 86, 95-100.	5.4	39
48	Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging. Scientific Reports, 2016, 6, 23749.	3.4	39
49	Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. Cancer Chemotherapy and Pharmacology, 2017, 79, 1179-1186.	2.4	39
50	Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. International Journal of Clinical Oncology, 2009, 14, 48-52.	2.3	38
51	Phase II Clinical Trial of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having a Therapeutic History of Platinum-based Chemotherapy: A Phase II Study of the Japanese Gynecologic Oncology Group. Japanese Journal of Clinical Oncology, 2008, 38, 777-785.	1.4	37
52	Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 2012, 69, 457-465.	2.4	37
53	No Alteration in DNA Topoisomerase I Gene Related to CPT-11 Resistance in Human Lung Cancer. Japanese Journal of Cancer Research, 1996, 87, 1280-1287.	1.6	36
54	Immunohistochemical profiles of brain metastases from breast cancer. Journal of Neuro-Oncology, 2008, 90, 223-228.	3.0	36

#	Article	IF	Citations
55	<scp>PIK</scp>3<scp>CA</scp> mutation profiling in patients with breast cancer, using a highly sensitive detection system. Cancer Science, 2018, 109, 2558-2566.	4.0	36
56	Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers. Breast Cancer, 2015, 22, 141-152.	3.0	34
57	Reversal of Cisplatin Resistance with Amphotericin B in a Non-small Cell Lung Cancer Cell Line. Japanese Journal of Cancer Research, 1991, 82, 747-751.	1.6	33
58	Evolution of frameworks for expediting access to new drugs in Japan. Nature Reviews Drug Discovery, 2016, 15, 293-294.	61.5	33
59	Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan). Journal of Cancer Research and Clinical Oncology, 1987, 113, 563-566.	2.6	32
60	Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents. Oncologist, 2016, 21, 508-513.	4.1	32
61	Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer. Cancer Chemotherapy and Pharmacology, 2001, 48, 42-46.	2.4	31
62	TERT promoter hotspot mutations in breast cancer. Breast Cancer, 2018, 25, 292-296.	3.0	30
63	Significant Association between Hand-Foot Syndrome and Efficacy of Capecitabine in Patients with Metastatic Breast Cancer. Biological and Pharmaceutical Bulletin, 2012, 35, 717-724.	1.5	29
64	Glutathione S-transferase-Ï€ gene expression and platinum drug exposure in human lung cancer. Cancer Letters, 2000, 156, 93-99.	7.3	28
65	Oncology drug clinical development and approval in Japan: the role of the pharmaceuticals and medical devices evaluation center (PMDEC). Critical Reviews in Oncology/Hematology, 2002, 42, 145-155.	4.5	28
66	Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Medical Oncology, 2009, 26, 344-349.	2.7	28
67	Molecular imaging using PET for breast cancer. Breast Cancer, 2016, 23, 24-32.	3.0	28
68	Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer. Supportive Care in Cancer, 2018, 26, 2161-2166.	2.3	28
69	Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid. Journal of Cancer Research and Clinical Oncology, 1995, 121, 729-738.	2.6	27
70	Contrasting Prognostic Implications of Platelet-Derived Growth Factor Receptor-Î² and Vascular Endothelial Growth Factor Receptor-2 in Patients with Angiosarcoma. Annals of Surgical Oncology, 2011, 18, 2841-2850.	2.0	27
71	A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. Gynecologic Oncology, 2012, 125, 307-311.	1.4	27
72	Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. Japanese Journal of Clinical Oncology, 2015, 45, 12-18.	1.4	27

#	Article	IF	Citations
73	Identification of Predictive Biomarkers for Response to Trastuzumab Using Plasma FUCA Activity and N-Glycan Identified by MALDI-TOF-MS. Journal of Proteome Research, 2009, 8, 457-462.	3.8	26
74	Efficacy of taxane regimens in patients with metastatic angiosarcoma. European Journal of Dermatology, 2011, 21, 539-545.	0.6	26
75	Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy. Breast, 2007, 16, 482-488.	2.3	25
76	Immunohistochemical Profile for Unknown Primary Adenocarcinoma. PLoS ONE, 2012, 7, e31181.	2.5	25
77	Impact of recent parity on histopathological tumor features and breast cancer outcome in premenopausal Japanese women. Breast Cancer Research and Treatment, 2013, 138, 941-950.	2.5	25
78	Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: A randomized phase II trial (PTEX46) toÂinvestigate the optimal duration of preoperative endocrine therapy. Breast, 2013, 22, 263-267.	2.3	24
79	The expression and clinical significance of ribophorin <scp>II</scp> (<scp>RPN2</scp>) in human breast cancer. Pathology International, 2015, 65, 301-308.	1.4	24
80	A phase I study of farletuzumab, a humanized anti-folate receptor Î± monoclonal antibody, in patients with solid tumors. Investigational New Drugs, 2015, 33, 332-340.	2.7	24
81	CYP2D6 Genotypeâ€“Guided Tamoxifen Dosing in Hormone Receptorâ€“Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study. Journal of Clinical Oncology, 2020, 38, 558-566.	15.4	24
82	Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging. Scientific Reports, 2017, 7, 12622.	3.4	23
83	CIS-diamminedichloroplatinum(II) inhibits p34cdc2 protein kinase in human lung-cancer cells. International Journal of Cancer, 1993, 55, 616-622.	5.4	22
84	Multicenter Phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. Journal of Orthopaedic Science, 2010, 15, 654-660.	1.2	22
85	Nucleostemin expression in invasive breast cancer. BMC Cancer, 2014, 14, 215.	2.6	22
86	Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population. Breast Cancer, 2019, 26, 492-498.	3.0	22
87	Radiation sensitivities in various anticancer-drug-resistant human lung cancer cell lines and mechanism of radiation cross-resistance in a cisplatin-resistant cell line. Journal of Cancer Research and Clinical Oncology, 1992, 119, 28-34.	2.6	21
88	Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan. International Journal of Clinical Oncology, 2006, 11, 421-425.	2.3	21
89	A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. European Journal of Cancer, 2019, 109, 84-91.	2.9	21
90	MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial. Clinical Pharmacology and Therapeutics, 2020, 108, 596-605.	4.9	21

#	Article	IF	Citations
91	Prognostic Factors in Young Japanese Women with Breast Cancer: Prognostic Value of Age at Diagnosis. Japanese Journal of Clinical Oncology, 2011, 41, 180-189.	1.4	20
92	Randomized phase II study of nabâ€paclitaxel as firstâ€line chemotherapy in patients with HER2â€negative metastatic breast cancer. Cancer Science, 2017, 108, 987-994.	4.0	20
93	Current Trends and Controversies over Pre-operative Chemotherapy for Women with Operable Breast Cancer. Japanese Journal of Clinical Oncology, 2007, 37, 1-8.	1.4	19
94	Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome. Breast Cancer Research and Treatment, 2009, 113, 307-313.	2.5	19
95	A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients. International Journal of Clinical Oncology, 2013, 18, 621-628.	2.3	19
96	MiRâ€1285â€5p/TMEM194A axis affects cell proliferation in breast cancer. Cancer Science, 2020, 111, 395-405.	4.0	19
97	Japanese universal health care faces a crisis in cancer treatment. Lancet Oncology, The, 2015, 16, 251-252.	10.8	18
98	Expectations of and recommendations for a cancer survivorship guideline in Japan: a literature review of guidelines for cancer survivorship. Japanese Journal of Clinical Oncology, 2019, 49, 812-822.	1.4	18
99	Establishment of a human leukemia subline resistant to the growth-inhibitory effect of 12-o-tetradecanoylphorbol 13-acetate (TPA) and showing non-P-glycoprotein-mediated multi-drug resistance. International Journal of Cancer, 1991, 48, 931-937.	5.4	17
100	Diagnosis of Complete Response to Neoadjuvant Chemotherapy Using Diagnostic Imaging in Primary Breast Cancer Patients. Breast Journal, 2005, 11, 311-316.	1.1	17
101	Immunohistochemical expression of HER1, HER3, and HER4 in HER2â€positive breast cancer patients treated with trastuzumabâ€containing neoadjuvant chemotherapy. Journal of Surgical Oncology, 2010, 101, 222-227.	1.7	17
102	Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy. Cancer Chemotherapy and Pharmacology, 2011, 68, 337-342.	2.4	17
103	Prognostic factors for stage IV hormone receptor-positive primary metastatic breast cancer. Breast Cancer, 2013, 20, 145-151.	3.0	17
104	Pathological features of tripleâ€negative breast cancers that showed progressive disease during neoadjuvant chemotherapy. Cancer Science, 2017, 108, 1520-1529.	4.0	17
105	Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1249-1257.	2.6	16
106	Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2146-2147.	6.7	16
107	Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 127-134.	2.4	16
108	Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients. Medical Oncology, 2007, 24, 425-430.	2.7	15

#	Article	IF	Citations
109	Long-term Outcome and Pattern of Relapse after Neoadjuvant Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 2-positive Primary Breast Cancer. Japanese Journal of Clinical Oncology, 2009, 39, 484-490.	1.4	15
110	Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy. Journal of Cancer Research and Clinical Oncology, 2009, 135, 551-557.	2.6	15
111	Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis. Cancer Chemotherapy and Pharmacology, 2012, 70, 391-397.	2.4	15
112	Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging. Oncotarget, 2018, 9, 18540-18547.	2.1	15
113	Increased phosphorylation of nuclear phosphoproteins in human lung-cancer cells resistant tocis-diamminedichloroplatinum(II). International Journal of Cancer, 1992, 50, 438-442.	5.4	14
114	Use of squamous cell carcinoma antigen as a biomarker of chemotherapy response in patients with metastatic cervical carcinoma. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 159, 394-398.	1.1	14
115	Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. Targeted Oncology, 2019, 14, 647-656.	3.7	14
116	ZK1, a Novel KrÃ¼ppel-Type Zinc Finger Gene, Is Induced Following Exposure to Ionizing Radiation and Enhances Apoptotic Cell Death on Hematopoietic Cells. Biochemical and Biophysical Research Communications, 1998, 249, 595-600.	2.2	13
117	Perception and needs of reproductive specialists with regard to fertility preservation of young breast cancer patients. International Journal of Clinical Oncology, 2015, 20, 82-89.	2.3	13
118	Drug induced interstitial lung disease in oncology phaseÂI trials. Cancer Science, 2016, 107, 1830-1836.	4.0	13
119	Fc-Gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab. Breast Cancer, 2016, 23, 624-632.	3.0	13
120	Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan. JCO Oncology Practice, 2021, 17, e416-e425.	2.8	13
121	Differential Expression of DNA Topoisomerase IIÎ± and IIÎ² Genes between Small Cell and Non-small Cell Lung Cancer. Japanese Journal of Cancer Research, 1998, 89, 855-861.	1.6	12
122	Translational studies for target-based drugs. Cancer Chemotherapy and Pharmacology, 2005, 56, 90-93.	2.4	12
123	Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy. Journal of Cancer Research and Clinical Oncology, 2006, 132, 635-642.	2.6	12
124	Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer. Journal of Cancer Research and Clinical Oncology, 2008, 134, 1199-1206.	2.6	12
125	Randomized Controlled Study Comparing Two Doses of Intravenous Granisetron (1 and 3 mg) for Acute Chemotherapy-induced Nausea and Vomiting in Cancer Patients: A Non-inferiority Trial. Japanese Journal of Clinical Oncology, 2009, 39, 443-448.	1.4	12
126	Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study. BMC Cancer, 2017, 17, 819.	2.6	12

#	Article	IF	Citations
127	Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential. International Journal of Cancer, 1997, 72, 295-300.	5.4	11
128	Weekly Epoetin Beta Maintains Haemoglobin Levels and Improves Quality of Life in Patients with Non-Myeloid Malignancies Receiving Chemotherapy. Japanese Journal of Clinical Oncology, 2008, 38, 214-221.	1.4	11
129	Grading system for lymph vessel tumor emboli: significant outcome predictor for patients with invasive ductal carcinoma of the breast who received neoadjuvant therapy. Modern Pathology, 2010, 23, 581-592.	5.6	11
130	Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study. Drug Safety, 2020, 43, 233-242.	3.2	11
131	BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. Breast Cancer Research and Treatment, 2020, 181, 323-329.	2.5	11
132	Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients. BMC Cancer, 2020, 20, 325.	2.6	11
133	In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines. Cancer Chemotherapy and Pharmacology, 1992, 30, 417-422.	2.4	10
134	A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. Cancer, 2005, 104, 1204-1212.	4.1	10
135	Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases. Molecular and Clinical Oncology, 2013, 1, 995-1001.	1.1	10
136	Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 745-752.	2.4	10
137	Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma. Therapeutic Innovation and Regulatory Science, 2018, 52, 334-338.	1.8	10
138	Alteration of Type II Regulatory Subunit of cAMP-dependent Protein Kinase in Human Cisplatin-resistant Cells as a Basis of Collateral Sensitivity to 8-Chloro-cAMP. Japanese Journal of Cancer Research, 1992, 83, 754-760.	1.6	9
139	Therapy-Related Acute Promyelocytic Leukemia Caused by Hormonal Therapy and Radiation in a Patient with Recurrent Breast Cancer. Japanese Journal of Clinical Oncology, 2008, 38, 567-570.	1.4	9
140	Phase II Study of Gemcitabine Monotherapy as a Salvage Treatment for Japanese Metastatic Breast Cancer Patients after Anthracycline and Taxane Treatment. Japanese Journal of Clinical Oncology, 2009, 39, 699-706.	1.4	9
141	Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer. World Journal of Surgery, 2009, 33, 44-51.	1.4	9
142	Randomized Phase II Study of Primary Systemic Chemotherapy and Trastuzumab for Operable HER2 Positive Breast Cancer. Clinical Breast Cancer, 2012, 12, 49-56.	2.6	9
143	A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin. Anti-Cancer Drugs, 2018, 29, 97-101.	1.4	9
144	Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Medical Oncology, 2019, 36, 58.	2.7	9

#	Article	IF	Citations
145	Invasive breast cancers in adolescent and young adult women show more aggressive immunohistochemical and clinical features than those in women aged 40â€“44Âyears. Breast Cancer, 2019, 26, 386-396.	3.0	9
146	Rare cancers in Japan: definition, clinical features and future perspectives. Japanese Journal of Clinical Oncology, 2020, 50, 970-975.	1.4	9
147	Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging. Scientific Reports, 2020, 10, 15535.	3.4	9
148	Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer. Oncology Letters, 2020, 20, 336.	1.8	9
149	Inhibition of Colony Formation of Drug-resistant Human Tumor Cell Lines by Combinations of Interleukin-2-activated Killer Cells and Antitumor Drugs. Japanese Journal of Cancer Research, 1989, 80, 265-270.	1.6	8
150	Detection of Proteins that Recognize Platinum-modified DNA Using Gel Mobility Shift Assay. Japanese Journal of Cancer Research, 1990, 81, 1210-1213.	1.6	8
151	Clinical Efficacy of S-1 in Pretreated Metastatic Breast Cancer Patients. Japanese Journal of Clinical Oncology, 2008, 38, 172-175.	1.4	8
152	Analysis of the clinicopathological prognosis of stage IVb cervical carcinoma. Oncology Reports, 2008, , .	2.6	8
153	The incidence and management of metachronous testicular germ cell tumors in patients with extragonadal germ cell tumors. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 319-324.	1.8	8
154	A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 1369-1374.	2.4	8
155	Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 doseâ€finding trials. Cancer Science, 2018, 109, 207-214.	4.0	8
156	Have We Found the Key to Unravel Treatment Development Lags for Rare Cancers?: <scp>MASTER KEY</scp> Project. Clinical Pharmacology and Therapeutics, 2019, 106, 491-492.	4.9	8
157	Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation. Case Reports in Oncological Medicine, 2020, 2020, 1-6.	0.4	8
158	In vitro antitumor effect of recombinant human tumor necrotizing factor on cultured human cancer cell lines and freshly isolated lung cancer cells by the human tumor clonogenic assay. Investigational New Drugs, 1987, 5, 353-9.	2.7	7
159	Serial Measurement of Sister Chromatid Exchanges in the Peripheral Lymphocytes of Patients with Lung Cancer Receiving Chemotherapy in Relation to Bone Marrow Toxicity. Japanese Journal of Cancer Research, 1989, 80, 783-786.	1.6	7
160	Phase I Study and Clinical Pharmacological Evaluation of Daily Oral Etoposide Combined with Carboplatin in Patients with Lung Cancer. Japanese Journal of Cancer Research, 1995, 86, 490-500.	1.6	7
161	Leptomeningeal metastasis from ovarian carcinoma successfully treated by the intraventricular administration of methotrexate. International Journal of Clinical Oncology, 2008, 13, 555-558.	2.3	7
162	Reply to V. Fusco et al. Journal of Clinical Oncology, 2011, 29, e523-e524.	15.4	7

#	Article	IF	Citations
163	A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane. International Journal of Clinical Oncology, 2013, 18, 590-597.	2.3	7
164	Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy. Translational Oncology, 2019, 12, 1386-1394.	3.8	7
165	HER3 protein expression as a risk factor for postâ€'operative recurrence in patients with earlyâ€'stage adenocarcinoma and adenosquamous carcinoma of the cervix. Oncology Letters, 2020, 20, 38.	1.8	7
166	Atypical tumor-stromal fibroblasts in invasive ductal carcinomas of the breast treated with neoadjuvant therapy. Human Pathology, 2011, 42, 998-1006.	2.3	6
167	Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing. Lung Cancer, 2019, 128, 20-25.	2.0	6
168	Toward global standardization of conducting fair investigations of allegations of research misconduct. Accountability in Research, 2020, 27, 327-346.	2.5	6
169	Prediction of response and prognostic factors for Ewing family of tumors in a low incidence population. Journal of Cancer Research and Clinical Oncology, 2008, 134, 389-395.	2.6	5
170	Relapse with Malignant Transformation After Chemotherapy for Primary Mediastinal Seminoma: Case Report. Japanese Journal of Clinical Oncology, 2009, 39, 456-459.	1.4	5
171	The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma. International Journal of Gynecological Cancer, 2017, 27, 1850-1855.	2.8	5
172	Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site. BMC Cancer, 2018, 18, 176.	2.6	5
173	The next step to approaching central nervous system metastasis in HER-2-positive metastatic breast cancer patients. Asia-Pacific Journal of Clinical Oncology, 2006, 2, 6-8.	1.3	4
174	Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy. Breast Cancer Research and Treatment, 2007, 103, 313-318.	2.5	4
175	Genomics, Health Care, and Society. New England Journal of Medicine, 2011, 365, 2339-2339.	30.1	4
176	Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy. Internal Medicine, 2017, 56, 2879-2882.	0.7	4
177	Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy. Investigational New Drugs, 2018, 36, 151-155.	2.7	4
178	Anticancer Agent-Induced Life-Threatening Skin Toxicities: A Database Study of Spontaneous Reporting Data. Oncologist, 2019, 24, 266-272.	4.1	4
179	Balancing Safety and Efficacy With Early Availability in the Regulation of Regenerative Medicine Product. Clinical Pharmacology and Therapeutics, 2021, 109, 1182-1185.	4.9	4
180	Second-line chemotherapy in patients with primary unknown cancer. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1185-1191.	2.6	3

#	Article	IF	Citations
181	De-identification Procedure and Sample Quality of the Post-clinical Test Samples at the Bio-repository of the National Cancer Center Hospital (NCCH) in Tokyo. Japanese Journal of Clinical Oncology, 2011, 41, 295-298.	1.4	3
182	A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines. Clinical Pharmacology and Therapeutics, 2019, 106, 803-809.	4.9	3
183	Future development of artificial organs related with cutting edge emerging technology and their regulatory assessment: PMDAâ€™s perspective. Journal of Artificial Organs, 2020, 23, 203-206.	1.0	3
184	Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs. Clinical and Translational Science, 2021, 14, 1015-1025.	3.1	3
185	Content Analysis of Oncology-Related Pharmaceutical Advertising in a Peer-Reviewed Medical Journal. PLoS ONE, 2012, 7, e44393.	2.5	3
186	The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site. Internal Medicine, 2019, 58, 1423-1428.	0.7	3
187	Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers. BMC Cancer, 2021, 21, 1131.	2.6	3
188	Challenges in Expediting the Development of Oncology Drugs. JCO Oncology Practice, 2023, 19, 216-217.	2.8	3
189	Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients. International Journal of Clinical Oncology, 2005, 10, 272-275.	2.3	2
190	A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer. Medical Oncology, 2011, 28, 434-440.	2.7	2
191	Outcomes of Japanese breast cancer patients treated with preâ€operative and postâ€operative anastrozole or tamoxifen. Cancer Science, 2012, 103, 491-496.	4.0	2
192	The influence of familial factors on the choice of the place of death for terminally ill breast cancer patients: a retrospective single-center study. Breast Cancer, 2016, 23, 797-806.	3.0	2
193	Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study. Cancer Chemotherapy and Pharmacology, 2018, 82, 275-283.	2.4	2
194	No-fault compensation schemes for COVID-19 medical products. Lancet, The, 2021, 397, 1707-1708.	12.1	2
195	Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers. Frontiers in Oncology, 2021, 11, 732525.	2.9	2
196	The Role of DNA-Microarray in Translational Cancer Research. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2005, 3, 201-216.	0.3	1
197	Re: Insulinlike growth factor 1 receptor: predictive factor in breast cancer patients treated with trastuzumab?. Human Pathology, 2005, 36, 449-449.	2.3	1
198	Personalized systemic treatment for breast cancer patients: is it a reality?. Breast Cancer, 2008, 15, 141-144.	3.0	1

#	Article	IF	Citations
199	Weekly Administration of Paclitaxel and Carboplatin in the Treatment of Advanced Ovarian or Peritoneal Cancers With Poor Performance Status. Clinical Ovarian Cancer & Other Gynecologic Malignancies, 2010, 3, 47-51.	0.4	1
200	Do investigators show selection biases when enrolling patients in phase I oncology registration trials?. Journal of Geriatric Oncology, 2011, 2, 25-30.	1.1	1
201	Reply to M.S. Aapro. Journal of Clinical Oncology, 2011, 29, e421-e423.	15.4	1
202	Back with a Vengeance: Microvascular Tumor Embolism. American Journal of Medicine, 2015, 128, 834-836.	1.4	1
203	Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study. Breast Cancer, 2019, 26, 39-46.	3.0	1
204	The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia. Clinical Pharmacology and Therapeutics, 2022, 111, 358-361.	4.9	1
205	Breast Cancer Stem Cell: Translating to the Clinic. , 2012, , 249-257.		1
206	Pemetrexed for malignant pleural mesothelioma: Is it a standard secondâ€line therapy?. Asia-Pacific Journal of Clinical Oncology, 2010, 6, 248-250.	1.3	0
207	Do Patients With Platinum-Resistant Epithelial Ovarian Cancer Benefit From Second-line Chemotherapy?. Clinical Ovarian Cancer & Other Gynecologic Malignancies, 2010, 3, 36-40.	0.4	0
208	The Incidence and Severity of Paclitaxel-induced Peripheral Neuropathy in Patients with Ovarian Cancer: a Retrospective Study. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.1	0
209	Clinical features and the result of treatment for brain metastases in advanced non-small cell lung cancer.. Japanese Journal of Lung Cancer, 1989, 29, 649-655.	0.1	0
210	Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine. Breast Cancer, 0, , .	3.0	0
211	A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer. Npj Breast Cancer, 2024, 10, .	5.4	0